- References (1)
Product namePLX4720, B-Raf inhibitor
DescriptionPotent B-Raf inhibitor
Biological descriptionPotent B-Raf inhibitor (IC50 values are 6.7, 13 and 160 nM for C-Raf-1Y340D/Y341D, B-RafV600E and B-Rafwild-type respectively). Shows antiproliferative effects. Shows antitumor effects in vivo. Orally active.
Storage instructionsStore at +4°C. The product can be stored for up to 12 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
- Research Area
- Alzheimer's Disease
- Signal transduction
- Raf kinase
This product has been referenced in:
- Michaelis M et al. Association between acquired resistance to PLX4032 (vemurafenib) and ATP-binding cassette transporter expression. BMC Res Notes 7:710 (2014). Read more (PubMed: 25300205) »
- Eum KH et al. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells. Mol Cell Biochem 372:65-74 (2013). Read more (PubMed: 22941213) »
- Shao Y & Aplin AE BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ 19:2029-39 (2012). Read more (PubMed: 22858545) »
- Oikonomou E et al. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One 6:e21632 (2011). Read more (PubMed: 21738740) »